Introduction {#s1}
============

Chordoma is an aggressive primary malignancy of the axial skeleton that is thought to originate from notochordal tissue[@pone.0101283-Nibu1]. The majority of these tumors occur in either the base of the skull (35%) or in the sacrum (50%), and these are typically managed with surgery and/or radiation[@pone.0101283-FernandezMiranda1]--[@pone.0101283-Park1]. Their clinical behavior is marked by slow growth and a predilection to recur despite surgical resection. Most patients with recurrent chordoma and almost all patients with metastasis will eventually die from this disease[@pone.0101283-Smoll1], [@pone.0101283-Schwab1]. Unfortunately, there is no effective systemic agent to control unresectable or metastatic chordoma and the development of new treatments is limited by our poor understanding of its biology[@pone.0101283-Schwab1]--[@pone.0101283-Lynch1].

The identification of driver mutations in malignancy, such as EGFR-mutated lung cancers, c-Kit mutated gastrointestinal stromal tumors, and ALK-translocated tumors, among others, has dramatically changed the treatment landscape for these diseases [@pone.0101283-Lynch1]--[@pone.0101283-Kwak1]. We hypothesize, therefore, that for a typically chemoresistant tumor such as chordoma where there is no effective systemic therapy, the identification of mutations in genes for which there exist a therapeutic strategy can inform the development of novel drugs. However, because of the rarity of patients with these tumors, comprehensive molecular understanding of chordoma pathogenesis is currently incomplete.

Karyotype studies observed chordomas with loss at chromosome 1p and 3p and gains involving chromosomes 7q, 20, 5q, and 12q [@pone.0101283-Dalpra1], [@pone.0101283-Scheil1]. Mobley et al. identified a cohort of poorly differentiated chordomas that lack SMARCB1/INI1 expression [@pone.0101283-Mobley1]. Cytogenetic evaluation using FISH showed that 3 of the 4 samples had deletion at this locus. Gene sequencing did not reveal any point mutations. Recently, Le et al. performed comparative genomic hybridization on 21 chordoma tumor samples to show frequent loss of chromosomal regions 9p21 and 10q23.3 [@pone.0101283-Le1]. They also genotyped for 56 point mutations occurring in 13 genes commonly associated with cancer, including CDKN2A (located in 9p21) and PTEN (located in 10q23.3) but did not identify any alterations in their cohort. We sought to expand on these observations by analyzing 45 chordoma samples via high throughput genotyping of cancer-associated genes known to play an important role in cancer.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

Institutional review board approval was obtained to retrospectively study these tumor samples from the Partners Human Research Committee, 116 Huntington Avenue, Suite 1002, Boston, MA 02116. The protocol number is 2007P-002464. The institutional review board waived the need to consent. Tumor specimens were obtained from the clinical archives of Dr. Francis Hornicek (Department of Orthopaedic Surgery, Massachusetts General Hospital) and the Massachusetts General Hospital Tissue Repository (<http://www.massgeneral.org/cancer/research/resourcelab.aspx?id=31>).

Chordoma tumor samples {#s2b}
----------------------

Tumor specimens were obtained from the clinical archives of Dr. Francis Hornicek (Department of Orthopaedic Surgery, Massachusetts General Hospital) and the Massachusetts General Hospital Tissue Repository (<http://www.massgeneral.org/cancer/research/resourcelab.aspx?id=31>).

Extraction of Genomic DNA {#s2c}
-------------------------

Extraction of DNA from chordoma tumor tissues and cell lines were performed using QIAamp DNA Micro kit (Qiagen) as previously described in prior publications [@pone.0101283-Choy1]. The extraction was carried out according to the manufacturer\'s instructions. DNA was preserved at −20°C until use.

Selection of Cancer Gene Mutations and OncoMap v3 Assay Design {#s2d}
--------------------------------------------------------------

Selection of cancer gene mutations for assay design and mass spectrometric genotyping were performed as previously described [@pone.0101283-Choy1]--[@pone.0101283-MacConaill1]. Multiple databases, including the Sanger Institute COSMIC database, PubMed, and The Cancer Genome Atlas (TCGA), were queried for known somatic oncogene and tumor suppressor gene mutations. Mutations were ranked in importance by frequency in cancers and across cancer subtypes, and genes with existing therapeutic modifiers were preferentially selected.

Primers for PCR amplification and the extension probe were designed using Sequenom MassARRAY Assay Design 3.0 and the resulting DNA sequences were (1) queried in the dbSNP database to avoid incorporation of SNPs during assay design, (2) confirmed through a BLAST-like alignment tool (BLAT) and modified where necessary to avoid pseudogene amplification[@pone.0101283-Kent1], and (3) synthesized unmodified using standard purification (Integrated DNA Technologies, Coralville, IA).

Mass Spectrometric Genotyping {#s2e}
-----------------------------

Primers and probes were pooled and then validated on control DNA derived from the CEPH panel of human HapMap DNAs (Coriell Institute) as well as a panel of human cell lines with known mutational status, as described previously[@pone.0101283-Thomas1]. Genomic DNA was quantified using Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, California), subjected to whole-genome amplification (WGA) using Qiagen Repli-g kit, and a post-WGA cleanup step was implemented using a Nucleofast Purification Kit (Macherey-Nagel). Mass spectrometric genotyping using iPLEX chemistries was performed as previously published [@pone.0101283-MacConaill1].

Candidate mutations were further filtered by manual review and selected for confirmation using multi-base extension homogenous Mass-Extend (hME) chemistry with plexing of ≤6 assays per pool. Conditions for hME validation were consistent with the methods described by MacConaill et al. 2009 [@pone.0101283-MacConaill1].

Array Comparative Genomic Hybridization (CGH) Analysis {#s2f}
------------------------------------------------------

Array CGH using the Agilent 4x180k CGH + SNP microarray (Santa Clara, CA) was previously described [@pone.0101283-Le1]. Copy number aberration calls were made with a minimum regional absolute average log base 2 ratio of 0.25 and minimum contiguous probe count of 5. All array data were manually reviewed for subtle changes.

Results {#s3}
=======

Characteristics of Clinical Tumor Samples {#s3a}
-----------------------------------------

A total of 45 DNA samples were derived from 40 patients who had undergone operative resections of their chordoma. Patient date of surgery (DOS), age, sex, tumor location, recurrence, and metastasis are catalogued in [Table 1](#pone-0101283-t001){ref-type="table"}. 28 specimens were obtained from fresh frozen tissue, and 17 were derived from FFPE blocks.
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###### Characteristics of Tumor Samples.

![](pone.0101283.t001){#pone-0101283-t001-1}

  Clinical data of DNA samples from chordoma tissues                                                    
  ---------------------------------------------------- ------------ ---- --- ----- ----- -------------- --------------------------------
  1                                                     12/23/1994   60   M   No    Yes      Sacrum     
  2                                                     9/22/1995    35   M   Yes   No       L1--L2     
  3                                                     10/2/1996    77   M   No    No       Sacrum     
  4                                                     10/30/1996   74   M   No    Yes      Sacrum              *PIK3CA*E545K
  5                                                     12/20/1996   55   M   No    No       Sacrum     
  6                                                      1/3/1997    73   M   No    Yes      Sacrum     
  7                                                      1/7/1997    58   M   Yes   No    Left scapula   *CDKN2A* R58\* *SMARCB1* R40\*
  8                                                     3/27/1998    60   M   Yes   No     Chest wall    *CDKN2A* R58\* *SMARCB1* R40\*
  9                                                      2/3/1999    48   M   No    No       Sacrum              *CTNNB1* T41A
  10                                                    5/12/1999    62   M   No    No       Sacrum     
  11                                                    2/11/2000    52   F   No    Yes        L3       
  12                                                    6/26/2000    63   M   No    No       Sacrum              *PTEN* R130\*
  13                                                    10/18/2000   51   M   Yes   No       Sacrum     
  14                                                    11/22/2000   71   F   No    No         L4       
  15                                                    4/25/2001    50   F   No    No       Sacrum     
  16                                                    5/16/2001    46   M   No    No       Sacrum     
  17                                                    7/25/2001    74   M   No    Yes      Sacrum     
  18                                                    9/19/2001    70   M   No    Yes      Sacrum               *NRAS* Q61R
  19                                                    4/12/2002    73   M   No    Yes      Sacrum     
  20                                                    10/30/2002   83   M   No    Yes      Sacrum     
  21                                                    12/6/2002    37   M   No    Yes      Sacrum     
  22                                                    1/15/2003    75   M   No    Yes      Sacrum     
  23                                                    5/20/2003    74   M   No    Yes      Sacrum     
  24                                                    1/30/2004    64   M   No    No       Sacrum     
  25                                                    12/14/2004   60   F   No    No       Sacrum     
  26                                                     5/3/2006    50   M   No    Yes     T12--L1     
  27                                                     7/5/2006    52   F   No    Yes      Sacrum     
  28                                                     8/3/2007    71   M   No    No       Sacrum     
  29                                                    5/16/2001    46   M   No    No       Sacrum     
  30                                                    8/16/2002    80   M   No    No       Sacrum     
  31                                                       N/A       58   F   No             Clivus     
  32                                                    2/14/2007    53   M   No    No     Skull base   
  33                                                    12/14/2004   60   F   No    No       Sacrum     
  34                                                    7/29/1993    41   M   No    Yes      Lumbar     
  35                                                    4/12/2002    73   M   No    Yes      Sacrum     
  36                                                     5/5/2006    70   M   No    Yes      Sacrum     
  37                                                     9/6/2006    73   M   No    No        T11       
  38                                                    6/26/2000    63   M   No    No       Sacrum     
  39                                                    7/30/2003    52   F   No    No       Sacrum               *ALK* A877S
  40                                                    10/2/1996    77   M   No    No       Sacrum     
  41                                                     8/3/2007    71   M   No    No       Sacrum     
  42                                                     8/4/1999    52   M   No    Yes      Lumbar     
  43                                                    5/21/2003    74   M   No    Yes      Sacrum     
  44                                                     1/6/2004    71   F   No    No      Cervical    
  45                                                    12/20/1996   55   M   No    No       Sacrum     

Samples 1--28 derived from fresh frozen tissue; Samples 29--45 derived from formalin fixed paraffin embedded tissue.

Genotype and CGH Analysis {#s3b}
-------------------------

Examples of the mass spectrometric readouts are shown in [Figure 1](#pone-0101283-g001){ref-type="fig"}. Mutation results are catalogued alongside patient characteristics in [Table 1](#pone-0101283-t001){ref-type="table"}. The identified mutations include: ALK (A877S), CTNNB1 (T41A) also known as β-Catenin, NRAS (Q61R), PIK3CA (E545K), PTEN (R130), CDKN2A (R58\*), and SMARCB1 (R40\*).

![Mass Spectrophotometry Plot: Observing a Mutation in SMARCB1.\
PCR products differ in mass depending on whether the probe extension detects a cytosine (C) or thymine (T). The figure in the right shows mass spec plot of an allele in SMARCB1 displaying a peak at both C and T. The left panel shows that most samples tested were homozygous with C, and 2 samples were heterozygous.](pone.0101283.g001){#pone-0101283-g001}

Among the 28 freshly frozen samples tested, 6 mutations were identified. Of the 17 FFPE samples tested, only 1 mutation (in ALK) was identified. Similar to our previously reported rates of detecting similar frequency of mutations between freshly frozen and paraffin embedded osteosarcoma tumor samples [@pone.0101283-Choy1], there appeared to be no difference in the rate of mutations in samples that were freshly frozen when compared to the samples of FFPE prepared (Fisher\'s exact test, p = 0.22 two tails). [Two samples (samples \#7 and 8 in]{.ul} [[Table 1]{.ul}](#pone-0101283-t001){ref-type="table"} [), taken from the same patient at different anatomic locations and surgical dates, each had the same mutations in both SMARCB1 and CDKN2A.]{.ul} When we performed CGH analysis on the samples with CDKN2A and PTEN mutations, we observed copy number losses at respective loci ([Figure 2](#pone-0101283-g002){ref-type="fig"}), demonstrating that these mutations occurred in regions of chromosomal loss.

![Selected View of aCGH Analyses (Chromosomes 9 and 10) from Two Cases.\
X-axis measures location along chromosome 9 (Panel A) or 10 (Panel B). Y-axis measures relative probe count. **A: aCGH showing heterozyogous copy loss at CDKN2A; B: aCGH showing heterozyogous copy loss at PTEN.**](pone.0101283.g002){#pone-0101283-g002}

Discussion {#s4}
==========

Chordomas have been previously described to have chromosomal aberrations and are characterized by chromosomal gains and losses at various regions throughout the genome [@pone.0101283-Dalpra1], [@pone.0101283-Scheil1], [@pone.0101283-Le1], [@pone.0101283-Diaz1]. A comprehensive genome-wide survey for high-yield mutations have not yet been performed across a large collection of chordomas. Array comparative genomic hybridization (aCGH) was used to analyze 21 chordoma tumor samples[@pone.0101283-Xia1] and observed large copy number losses involving chromosomes 1p, 3, 4, 9, 10, 13, 14, and 18 [@pone.0101283-Le1]. In that study, a focused analysis of 11 cancer-related genes did not reveal any new mutations in DNA sequence. Diaz et al. performed a whole-genome single-nucleotide polymorphism microarray analysis of 21 clival chordoma samples to confirm CGH findings by others that chromosome 3 aneuploidy and chromosome 9p deletion occurs (albeit less frequently than in sacral chordomas)[@pone.0101283-Diaz1].

With current technology, whole-genome sequencing of large collections of chordomas is costly and laborious. Thus, we aimed to broaden our mutational screen while focusing only on those genetic alterations that have been previously implicated as tumorigenisis drivers in other tumor types with the overall goal of identifying new mutations that could direct further research into chordoma therapeutic discovery. Some of the mutations identified in this study are in genes well-known for their role as tumor suppressors, such as PTEN and CDKN2A. Interestingly, both of these genes lie in chromosomal regions that were frequently found to have copy number losses in the recent CGH array analysis (9p21 for CDKN2A and 10q23.3 for PTEN) at a rate of \>80% for each. Therefore, we performed CGH in the samples containing mutations in PTEN and CDKN2A and found chromosomal loss at each loci in the respective samples. Interestingly, 33% of samples tested in Le et al. collection found complete loss of both copies of CDKN2A -- arguing that either a point mutation at CDKN2A or complete copy loss of CDKN2A can lead to LOH at this locus [@pone.0101283-Le1]. We therefore infer that loss of heterozygosity (LOH) at these loci can potentially be a tumorigenic event for the development of chordoma.

SMARCB1 is a subunit of the ATP-dependent chromatin remodeling complex SWI/SNF, a powerful epigenetic tumor suppressor, which directly antagonizes the histone methyltransferase EZH2. Mutations in SWI/SNF members are increasingly being recognized in malignancies where they are now thought by some groups to be more common than inactivating mutations in p53 [@pone.0101283-Kadoch1], [@pone.0101283-Kadoch2]. SMARCB1 also regulates the cell-cycle by activating CDKN2A, and its loss leads to upregulation of EZH2 a molecule that is being targeted by several inhibitors that are currently undergoing clinical testing [@pone.0101283-Wilson1]--[@pone.0101283-Knutson1]. SMARCB1 is known to be disrupted in malignant rhabdoid tumors, round cell soft-tissue sarcomas (most were a subset of tumors resembling extraskeletal myxoid chondrosarcoma with rhabdoid features, epithelioid sarcomas, and schwannomatosis [@pone.0101283-Knutson1]--[@pone.0101283-Kuwahara1].

These tumors, like chordomas, are groups of rare neoplasms for which no effective therapy is known. Mobley et al. observed that in poorly differentiated chordomas, expression of SMARCB1 is also lacking. They used FISH to evaluate the SMARCB1 locus at chromosome 22q and found deletion in 3 of 4 samples[@pone.0101283-Kuwahara1]. We therefore also infer that when SMARCB1 mutations coincide in areas of chromosomal loss, loss of heterozygosity can also be a tumorigenic event.

Several of the mutations found in our study, such as ALK, PIK3CA, and CTNNB1, each have inhibitors that are either commercially available, such as the ALK inhibitor XALKORI (crizotinib), or have multiple inhibitors currently under active clinical development[@pone.0101283-Yang1]--[@pone.0101283-ElKhoueiry1]. Observations such as ours suggest the clinical utility of performing a genotype directed clinical trial to test new kinase inhibitors in this disease population.

In conclusion, we observed chordomas with point mutations in tumor suppressor genes in areas of frequent chromosomal loss and in oncogenes with commercially available inhibitors. The former suggests possible mechanisms for chordoma tumorigenesis, the latter suggests possibilities for novel therapies. Further studies need to be done in order to establish these genes as important biomarkers or targets in chordoma. The ideal study would be a complete genome sequencing effort involving many more chordoma samples. We hope that this initial sign of successful genotyping in the largest collection of human chordoma tumor samples to date may ignite enthusiasm to further investigations into the molecular pathology of this disease that currently has no effective medical therapy.
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